Breaking News Instant updates and real-time market news.

AGN

Allergan

$227.55

-4.81 (-2.07%)

, VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Allergan, Vitae Pharmaceuticals announce expiration of HSR waiting period

Allergan (AGN) and Vitae Pharmaceuticals (VTAE) announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter.

AGN

Allergan

$227.55

-4.81 (-2.07%)

VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

AGN Allergan
$227.55

-4.81 (-2.07%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
VTAE Vitae Pharmaceuticals
$20.99

0.02 (0.10%)

09/15/16
BMOC
09/15/16
DOWNGRADE
BMOC
Market Perform
Vitae Pharmaceuticals downgraded to Market Perform at BMO Capital
Vitae Pharmaceuticals (VTAE) has agreed to be acquired by Allergan (AGN) for $21 per share in cash.
09/15/16
WELS
09/15/16
DOWNGRADE
WELS
Market Perform
Vitae downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Vitae Pharmaceuticals (VTAE) to Market Perform following the proposed acquisition of Allergan (AGN). The deal's valuation is "relatively cheap and leaves open some possibility of a competing bid and modest price bump," Birchenough tells investors in a research note. He lowered his price target range for the shares to $21-$27 from $27-$32.
09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Kadmon has positive read through from Allergan deal, says JMP Securities
JMP Securities analyst Michael King says that Allergan's (AGN) acquisition of Vitae Pharmaceuticals (VTAE) bodes well for Kadmon's (KDMN) ROCK inhibitor KD025 for patients with psoriasis. The analyst says that the main driver for the Vitae deal was its oral RORyt inhibitor VTP-43742 which could become a psoriasis treatment. There are "mechanistic similarities" between Vitae's drug and Kadmon's psoriasis drug candidate KD025, King wrote. He reiterates a $16 price target and Outperform rating on Kadmon.
09/20/16
PIPR
09/20/16
DOWNGRADE
PIPR
Neutral
Vitae Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Vitae Pharmaceuticals (VTAE) to Neutral citing Allergan's (AGN) takeover of the company. The analyst does not expect other offers to emerge.

TODAY'S FREE FLY STORIES

08:15
06/26/17
06/26
08:15
06/26/17
08:15
General news
Durable Goods Orders to be reported at 08:30 »

May Durable Goods Orders…

08:15
06/26/17
06/26
08:15
06/26/17
08:15
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

May Durable Goods Orders…

08:15
06/26/17
06/26
08:15
06/26/17
08:15
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

May Chicago Fed National…

KHC

Kraft Heinz

$88.85

-0.25 (-0.28%)

, CAG

Conagra Brands

$37.23

0.14 (0.38%)

08:14
06/26/17
06/26
08:14
06/26/17
08:14
Recommendations
Kraft Heinz, Conagra Brands, Dean Foods, Nestle, General Mills, Pinnacle Foods analyst commentary  »

JPMorgan sees Kraft,…

KHC

Kraft Heinz

$88.85

-0.25 (-0.28%)

CAG

Conagra Brands

$37.23

0.14 (0.38%)

DF

Dean Foods

$17.71

0.08 (0.45%)

NSRGY

Nestle

$84.83

0.4 (0.47%)

GIS

General Mills

$55.94

-0.06 (-0.11%)

PF

Pinnacle Foods

$61.92

0.4 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 12

    Jul

ARNC

Arconic

$25.54

0.24 (0.95%)

08:12
06/26/17
06/26
08:12
06/26/17
08:12
Periodicals
Arconic supplied flammable panels for use in Grenfell Tower, Reuters reports »

Six emails dating from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$10.15

-1.39 (-12.05%)

08:12
06/26/17
06/26
08:12
06/26/17
08:12
Hot Stocks
Ocular Therapeutix reports inducement grant under NASDAQ Listing Rule 5635(c)(4) »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

XLF

Financial Select Sector

$23.89

-0.09 (-0.38%)

, XLV

Health Care Select Sector SPDR

$80.47

-0.12 (-0.15%)

08:11
06/26/17
06/26
08:11
06/26/17
08:11
Technical Analysis
Technical View: SPDR S&P 500 ETF Trust breaks pivot high »

The SPDR S&P 500 ETF…

XLF

Financial Select Sector

$23.89

-0.09 (-0.38%)

XLV

Health Care Select Sector SPDR

$80.47

-0.12 (-0.15%)

SPY

SPDR S&P 500 ETF Trust

$243.13

0.29 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$6.06

0.24 (4.12%)

08:09
06/26/17
06/26
08:09
06/26/17
08:09
Hot Stocks
ImmunoGen presents data from Phase 1 study of IMGN779 in AML »

ImmunoGen presented data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

CBIO

Catalyst Biosciences

$4.53

0.02 (0.44%)

08:09
06/26/17
06/26
08:09
06/26/17
08:09
Hot Stocks
Catalyst says new data support ongoing trial of CB 2679d in hemophilia B »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NLSN

Nielsen

$37.46

0.32 (0.86%)

, FRED

Fred's

$10.25

0.38 (3.85%)

08:08
06/26/17
06/26
08:08
06/26/17
08:08
Hot Stocks
Nielsen, Fred's expand strategic analytics relationship »

Nielsen (NLSN) and…

NLSN

Nielsen

$37.46

0.32 (0.86%)

FRED

Fred's

$10.25

0.38 (3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 27

    Jul

ATOS

Atossa Genetics

$0.53

0.0228 (4.50%)

08:07
06/26/17
06/26
08:07
06/26/17
08:07
Hot Stocks
Atossa says receives 'positive' interim safety assessment in Phase 1 study »

Atossa Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNF

FNF Group

$44.58

0.43 (0.97%)

08:07
06/26/17
06/26
08:07
06/26/17
08:07
Hot Stocks
FNF Group acquires majority stake in Title Guaranty of Hawaii »

Fidelity National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$95.91

1.05 (1.11%)

08:07
06/26/17
06/26
08:07
06/26/17
08:07
Upgrade
Visteon rating change  »

Visteon upgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$66.05

0.96 (1.47%)

08:07
06/26/17
06/26
08:07
06/26/17
08:07
Hot Stocks
Fortune Brands Home & Security appoints Patrick Hallinan CFO »

Fortune Brands Home &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UN

Unilever; also tag UL

$55.68

0.08 (0.14%)

, UL

Unilever; also tag UN

$54.35

0.03 (0.06%)

08:06
06/26/17
06/26
08:06
06/26/17
08:06
Periodicals
Unilever threatens to pull ads from Google, Facebook, Times of London says »

Unilever (UN, UL) has…

UN

Unilever; also tag UL

$55.68

0.08 (0.14%)

UL

Unilever; also tag UN

$54.35

0.03 (0.06%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

FB

Facebook

$155.07

1.67 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

VSAT

ViaSat

$66.73

0.73 (1.11%)

08:06
06/26/17
06/26
08:06
06/26/17
08:06
Hot Stocks
ViaSat awarded $88.3M in contracts from SPAWAR »

ViaSat has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBRV

Nabriva Therapeutics

$10.55

0.05 (0.48%)

, TRVN

Trevena

$2.52

0.03 (1.20%)

08:06
06/26/17
06/26
08:06
06/26/17
08:06
Hot Stocks
Nabriva names CEO Colin Broom, Trevena CCO Carrie Bourow to board »

Nabriva Therapeutics…

NBRV

Nabriva Therapeutics

$10.55

0.05 (0.48%)

TRVN

Trevena

$2.52

0.03 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

  • 26

    Sep

VOXX

VOXX

$7.85

0.25 (3.29%)

, TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
VOXX to sell Hirschmann Car Communication to TE Connectivity »

VOXX International (VOXX)…

VOXX

VOXX

$7.85

0.25 (3.29%)

TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOFT

Hooker Furniture

$39.40

-0.85 (-2.11%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Conference/Events
Hooker Furniture management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

NEOT

Neothetics

$2.32

0.0501 (2.21%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
Neothetics: LIPO-202 did not demonstrate improvement in Phase 2 trial »

Neothetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTT

GTT Communications

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
GTT Communications to acquire Global Capacity »

GTT Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAFD

8point3 Energy

$14.62

0.22 (1.53%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
8point3 Energy increases quarterly distribution 3% to 26.42c per share »

8point3 Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

, ATRS

Antares Pharma

$3.21

0.2 (6.64%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
AMAG Pharmaceuticals reports FDA filing acceptance for Makena sNDA »

AMAG Pharmaceuticals…

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

ATRS

Antares Pharma

$3.21

0.2 (6.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 20

    Oct

VOXX

VOXX

$7.85

0.25 (3.29%)

, TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
Breaking Hot Stocks news story on VOXX, TE Connectivity »

VOXX to sell Hirschmann…

VOXX

VOXX

$7.85

0.25 (3.29%)

TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANY

Sphere 3D

$0.17

-0.0854 (-33.31%)

08:03
06/26/17
06/26
08:03
06/26/17
08:03
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.